News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
SBP GROUP Innovative Drug Naldemedine Approved for Marketing by NMPA
SBP GROUP (01177.HK) announced that Naldemedine (generic name: Naldemedine Tosylate Tablets; brand name: Symproic), a Class 1 innovative drug exclusively licensed by the Group̵...
Reset
Send
The window will close in 5 seconds
SBP GROUP Innovative Drug Naldemedine Approved for Marketing by NMPA
Close
Recommend
12
Positive
21
Negative
5
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

SBP GROUP (01177.HK)  -0.070 (-1.414%)    Short selling $106.78M; Ratio 31.249%   announced that Naldemedine (generic name: Naldemedine Tosylate Tablets; brand name: Symproic), a Class 1 innovative drug exclusively licensed by the Group’s subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), has been approved for marketing by China’s National Medical Products Administration (NMPA) for the treatment of opioidinduced constipation (OIC) in adults.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-02 16:25.)

Related News M Stanley Cuts SBP GROUP (01177.HK) TP to HKD7.8, Rating Overweight

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.